Toxicity assessment of intratumoral injection of the herpes simplex type I thymidine kinase gene delivered by retrovirus in patients with refractory cancer

Molecular Therapy

Volumn 4, Issue 2, 2001, Pages 157-160

  Singh, Sandeep ^a   Cunningham, Casey ^a,b,c   Buchanan, Angela ^a   Jolly, Doug J ^d   Nemunaitis, John ^a,b,c  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c Mary Crowley Medical Research Center   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cancer; Herpes simples; Intratumoral injection; Retroviral; Thymidine kinase; Type I

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; GANCICLOVIR; GANCICLOVIR DERIVATIVE; GANCICLOVIR TRIPHOSPHATE; INTERLEUKIN 12; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BREAST CANCER; CACHEXIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELLULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FEMALE; FEVER; GENE CONSTRUCT; GENE TARGETING; GENETIC TRANSFECTION; HEMATURIA; HERPES SIMPLEX VIRUS 1; HUMAN; HYPOTENSION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; MEDICAL ASSESSMENT; MELANOMA; MUSCLE WEAKNESS; NAUSEA; OSTEOSARCOMA; PAIN; PAIN ASSESSMENT; PHOSPHORYLATION; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; RETROVIRUS; SEPSIS; THROMBOSIS; VIRUS ENVELOPE; VIRUS REPLICATION;

EID: 0034882131     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0430     Document Type: Article

References (35)

1. Drug sensitivity ("suicide") genes for selective cancer therapy
2. Gene therapy of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wildtype retrovirus kills other tumor cells
3. In vivo gene transfer with retroviral vector-produced cells for treatment of experimental brain tumors
4. Thymidine kinase-mediated killing of rat brain tumors
5. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
6. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats
7. Systemic gene therapy of murine melanoma using tissue specific expression of the HSV-tk gene involves an immune component
8. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
9. A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells
10. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy
11. A Phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma
12. A Phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma
13. Transfer of genes to humans: Early lessons and obstacles to success
14. An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer
15. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury
16. Intraperitoneal in vivo gene therapy to deliver α 1-antitrypsin to the systemic circulation
17. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
18. The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene
19. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats
20. Establishment of parameters for optimal transduction efficiency and antitumor effects with purified high titer HSV-tk retroviral vector in established solid tumors
21. Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: Improved safety and high titer
22. Prospects for herpes simplex virus thymidine kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer
23. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer
24. A Phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous melanoma
25. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene
26. Herpes simplex thymidine kinase gene transfer is required for complete regression of murine colon adenocarcinoma
27. Prodrug activation enzymes in cancer gene therapy
28. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: The woodchuck animal model
29. Co-transduction of herpes simplex virus thymidine kinase gene and human IL-2 gene into mouse ovarian cancer cell line, OVHM
30. Gene therapy of malignant gliomas: A Phase I study of IL-4-HSV-tk gene-modified autologous tumor to elicit an immune response
31. Combined gene therapy with suicide gene and IL-12 is more efficient than therapy with the gene alone in a murine model of hepatocellular carcinoma
32. Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-α retroviral vector in melanoma patients
33. Long-term follow-up of retroviral vector-administered interferon-α (IFN-α) gene in metastatic melanoma
34. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer
35. Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus